On the contrary, pharmacological SGLT2:SGLT1 selectivity ratio significantly correlated with stroke outcomes, with lower SGLT2 selectivity (i.e. more pronounced inhibitory effect on SGLT1) corresponding with reduced risk. This evidence concerns the gene SLC5A1 and stroke disorder.